KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Operating Income (2016 - 2026)

Bio-Rad Laboratories has reported Operating Income over the past 18 years, most recently at $34.1 million for Q1 2026.

  • Quarterly Operating Income rose 43.88% to $34.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $57.6 million through Mar 2026, down 76.77% year-over-year, with the annual reading at $47.2 million for FY2025, 82.45% down from the prior year.
  • Operating Income was $34.1 million for Q1 2026 at Bio-Rad Laboratories, up from -$118.9 million in the prior quarter.
  • Over five years, Operating Income peaked at $146.4 million in Q1 2022 and troughed at -$118.9 million in Q4 2025.
  • The 5-year median for Operating Income is $77.1 million (2025), against an average of $68.9 million.
  • Year-over-year, Operating Income soared 45.16% in 2022 and then crashed 303.95% in 2025.
  • A 5-year view of Operating Income shows it stood at $118.7 million in 2022, then decreased by 19.66% to $95.3 million in 2023, then crashed by 38.84% to $58.3 million in 2024, then crashed by 303.95% to -$118.9 million in 2025, then skyrocketed by 128.68% to $34.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Operating Income are $34.1 million (Q1 2026), -$118.9 million (Q4 2025), and $65.3 million (Q3 2025).